Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

0.0%

-86.6% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
1(33.3%)
Phase 2
1(33.3%)
Phase 3
1(33.3%)
3Total
Phase 1(1)
Phase 2(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07689942Unknown

Expanded Access to 0.5 mg eRapa for Familial Adenomatous Polyposis

Role: lead

NCT06950385Phase 3Recruiting

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

Role: collaborator

NCT05324501Phase 1Terminated

A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma

Role: lead

NCT04230499Phase 2Active Not Recruiting

Trial of ERapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance

Role: collaborator

All 4 trials loaded